A046210 Stock Overview
Panagene Inc. develops products in the field of molecular diagnostics in South Korea.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩3,700.00|
|52 Week High||₩6,550.00|
|52 Week Low||₩3,100.00|
|1 Month Change||-5.61%|
|3 Month Change||-17.23%|
|1 Year Change||-40.61%|
|3 Year Change||-12.74%|
|5 Year Change||-38.23%|
|Change since IPO||-62.89%|
Recent News & Updates
|A046210||KR Biotechs||KR Market|
Return vs Industry: A046210 underperformed the KR Biotechs industry which returned -34.3% over the past year.
Return vs Market: A046210 underperformed the KR Market which returned -14.3% over the past year.
|A046210 Average Weekly Movement||4.6%|
|Biotechs Industry Average Movement||6.5%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.1%|
Stable Share Price: A046210 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A046210's weekly volatility (5%) has been stable over the past year.
About the Company
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products.
Panagene Fundamentals Summary
|A046210 fundamental statistics|
Is A046210 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A046210 income statement (TTM)|
|Cost of Revenue||₩27.82b|
Last Reported Earnings
Sep 30, 2013
Next Earnings Date
|Earnings per share (EPS)||0|
|Net Profit Margin||0.00%|
How did A046210 perform over the long term?See historical performance and comparison
Is Panagene undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
In this section, we usually try to help investors determine whether Panagene is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Panagene has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Panagene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Panagene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Panagene performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical Pharmaceuticals & Biotech annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Panagene has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
How is Panagene's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
In this section we usually analyse Panagene's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Panagene has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
What is Panagene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A046210's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A046210's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A046210's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A046210's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A046210 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Sung-Ki Kim (60 yo)
Sung-Ki Kim serves as the Chief Executive Officer and President of Panagene Inc. Sung-Ki Kim serves as Executive Officer of Daedong Industrial Co., Ltd. Sung-Ki Kim graduated from Seoul National University...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Panagene Inc.'s employee growth, exchange listings and data sources
- Name: Panagene Inc.
- Ticker: A046210
- Exchange: KOSDAQ
- Founded: 1976
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩122.280b
- Shares outstanding: 32.14m
- Website: https://www.panagene.com
Number of Employees
- Panagene Inc.
- 54, Techno 10-ro
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/12 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.